hypertensive and had miosis. A toxicologic workup was negative for other substances. Naloxone administration failed to lead to pupillary dilatation. Over the following 3 hours, 2 partial complex seizures involving his left upper extremity were observed; intravenous (IV) lorazepam promptly stopped them. Neurological examination, EEG and brain CT scans were noncontributory and failed to reveal other etiologic processes. Bloodwork was notable for a slightly elevated activated partial thromboplastin time (43.6 seconds, range 28.1 to 42.1 seconds), with normal platelet count, prothrombin time, and international normalized ratio.
Owing to his obtunded state, he was intubated and admitted to the intensive care unit. He required IV antibiotics for aspiration pneumonia. Four days later, because he had difficulties weaning off the ventilator, a ventilation-perfusion lung scan was ordered and revealed multiple disseminated pulmonary emboli. Further workup also found bilateral deep venous thromboses. Hematological consultation confirmed the presence of anticardiolipin antibodies, leading to a diagnosis of underlying antiphospholipid syndrome and recommendation that he receive lifetime warfarin therapy. Because his psychosis persisted, haloperidol 2 mg daily was initiated, with beneficial effect. Following discharge, the patient was lost to follow-up.
Discussion
Common adverse effects of olanzapine include dizziness, somnolence, increased appetite, and weight gain. Although the drug has an overall favourable safety profile, experience with toxicity is still emerging (1) . Weight gain over long-term use, combined with prolonged stupor and immobility following the overdose, may have contributed to our patient's thrombosis. The underlying antiphospholipid syndrome further elevated his risk (2) . Although not routinely tested, up to one-third of patients presenting with psychosis have an underlying antiphospholipid syndrome (4) . Other relevant risk factors for clot formation in psychiatric patients (which did not occur in this patient) include smoking, phenothiazine prescription, and use of restraints (3).
One other death has been described in a patient receiving olanzapine (10 mg daily). This patient died from disseminated intravascular coagulation following prolonged status epilepticus (5) . Although an autopsy was performed, testing for anticardiolipin antibodies was not reported (4) . Some authors have dismissed convulsions and clotting abnormalities as unlikely following olanzapine intoxication (6) . However, olanzapine is structurally related to clozapine, which has one of the highest incidences of seizure occurrence among the atypical antipsychotics (1) . Therefore, on the basis of emerging data, we recommend vigilance for seizures and clotting abnormalities with high dosages of olanzapine and in patients with underlying coagulopathies.
Nadeem H Bhanji, BScPharm, MD Guy Chouinard, MD, MSc, FRCPC Lawrence Hoffman, MD, CM, FRCPC Howard C Margolese, MD, CM, MSc, FRCPC Montreal, Quebec
Posttraumatic Mood Disorder: A New Concept
Dear Editor: A recent study found that comorbidity of posttraumatic stress disorder (PTSD) and depression was associated with global psychosocial impairment, distress, social impairment, and occupational disability and that this distinction remained when the comorbid group was compared directly with a pure PTSD group (1) . These findings raised the question whether comorbid PTSD and depression should be recognized as a core posttraumatic affective disorder.
Neurobiological findings support the notion that posttraumatic mood disorder can be recognized as a separate disorder. Maes and others reported an association between PTSD with concurrent major depression and lower affinity of alpha 2 adrenoreceptors, as well as higher plasma tyrosine availability to the brain, not found in patients suffering from PTSD alone (2) . This indicates that monoaminergic mechanisms may play a role in the pathophysiology of comorbid PTSD and depression. Woodward and others found that patients with comorbid PTSD and depression exhibited less slow wave sleep and less facial (mentalis) electromyographic activity, compared with PTSD patients without comorbid depression (3) .
Cortisol response to placebo or fenfluramine was examined in depression patients with or without comorbid PTSD and in a control group of healthy volunteers (4) . Depression patients with comorbid PTSD had the lowest plasma cortisol; depression patients without comorbid PTSD had the highest plasma cortisol; and healthy volunteers had intermediate levels. Sher and others compared the effect of age on postchallenge cortisol levels in depression patients with or without comorbid PTSD and in healthy volunteers (5) . We found that cortisol levels increased with age in depression patients with PTSD alone; they did not increase in depression patients with comorbid PTSD or in healthy volunteers. Family studies suggest a shared liability for PTSD and major depression, with familial loading for major depression predicting chronic PTSD in trauma survivors (6) . Future studies of comorbid PTSD and depression should include large samples, independent ratings of exposure severity, ratings of psychological health done independently of exposure, reliable information on the timing of the disorders' onset and offset, and measures of putative biological markers (7) . Studies of comorbid PTSD and depression may produce important results.
Leo Sher, MD New York, New York

Proinflammatory Cytokines: A Common Denominator in Depression and Somatic Symptoms?
Dear Editor: Over the last decade, psychoneuroimmunological studies have reported the presence of immune disturbances in several psychiatric disorders and confirmed the effects of proinflammatory cytokines on neurobehavioural processes (1) . Reported successes with antidepressant use in treating the somatic symptoms of functional somatic syndromes may point to a shared causal, but hitherto unknown, factor between these disorders and depression (2) . We argue that abnormal proinflammatory cytokine production may be a shared causal factor. Our hypothesis rests on 3 facts. First, cytokines can influence cerebral function and cytokine receptors have been shown on many cerebral structures (3) . Microglial cells and astrocytes can produce cytokines (4). Among the cytokines with effects that could have a bearing on psychopathology are the proinflammatory cytokines IL-1, IL-2, IL-6, and TNF (1). Second, abnormal proinflammatory cytokine activity has been implicated in major depression and reported in some functional somatic syndromes (5, 6) . Third, antidepressants that are used successfully in treating depression, and for which partial success has been reported with regard to the somatic symptoms of functional somatic syndromes, have antiinflammatory properties. Antidepressants have, in fact, been shown to have immunomodulatory effects (7) , and all antidepressant drugs, irrespective of their pharmacologic class, are able to attenuate the behavioural and neuroendocrine effects of immune activation (8) . We therefore conclude that proinflammatory cytokine production may be a shared causal factor in depression and functional somatic syndromes and that the antiinflammatory properties of antidepressants may account for their reported success in the treatment of these disorders.
